Oncologists (Cancer Specialists) in Pantai Hospital (Bangsar) Kuala Lumpur (KL)

  • Dr John Low Seng Hooi
  • Dr Lam Kai Seng
  • Dr Christina Ng Van Tze
  • Dr Mastura Md Yusof
  • Dr Ahmad Radzi Ahmad Badruddin
  • Dato' Dr Mohd Ibrahim A. Wahid
  • Dr Joseph K. Joseph 
Gynaecological Oncology
  • Dr Paul Ng Hock Oon

Related terms: Cervical cancer, Ovarian cancer, Uterine Cancer, Breast cancer, Lung cancer, Prostate cancer, Nasopharyngeal cancer (NPC)

 Back to Find other medical specialists in Pantai Hospital (Bangsar) Kuala Lumpur

Comments

Post a Comment

Popular posts from this blog

CagriSema and Muscle Loss: What the 2026 Evidence Actually Shows

Image
Updated: October 27, 2026  |  Evidence review: REDEFINE 1, Novo Nordisk disclosures, and current obesity-treatment guidance CagriSema has attracted attention for the amount of weight people lost in the phase 3 REDEFINE 1 trial. A more clinically important question is whether that weight loss also preserves muscle, strength and physical function. The evidence supports a measured conclusion: CagriSema produced substantial fat loss, but the published body-composition results do not establish that it eliminates muscle loss or preserves skeletal muscle better than semaglutide or tirzepatide. The distinction matters because fat mass, lean soft tissue, skeletal muscle and muscle function are related but not interchangeable outcomes. What readers should know In REDEFINE 1, mean weight loss at week 68 was 20.4% using the treatment-policy estimand and 22.7% using the trial-product estimand. A small DXA subgroup analysis attributed approximatel...
Read more

How to Prevent Muscle Loss on GLP-1 Drugs: Protein, Resistance Training & Body Composition Guide (2026)

Image
Home › GLP-1 Hub > GLP-1 Muscle Loss By Dr. Frank Yap, MD  |  Last updated: October 2026  |  Purpose: evidence and safety education, not individual medical advice GLP-1-based medicines have changed the treatment of obesity by making substantial, sustained weight loss possible for many people. But as the scale goes down, an important question follows: How much of the weight being lost is fat, and how much is lean tissue? This matters because long-term health is not determined by body weight alone. Preserving skeletal muscle, strength, physical function and nutritional adequacy is particularly important during substantial weight loss. The good news is that current evidence does not support the idea that GLP-1 therapies simply “eat away” muscle. Most weight lost with semaglutide and tirzepatide is fat mass. At the same time, measurable reductions in lean mass can occur, particularly during large or rapid weight loss. The ...
Read more

Retatrutide and Muscle Loss: What the Research Shows and How to Preserve Muscle (2026)

Image
Does retatrutide cause muscle loss? The available evidence suggests that retatrutide-associated weight loss includes a reduction in lean mass, as occurs with other effective obesity treatments. However, the available studies do not establish how much actual skeletal muscle an individual will lose, whether the loss affects muscle function, or how much can be prevented through nutrition and exercise. In a published Phase 2 body-composition substudy involving adults with type 2 diabetes, researchers observed substantial fat-mass reductions alongside reductions in lean mass. The results do not show that retatrutide uniquely damages muscle, but they also do not justify assuming that very large weight losses will preserve muscle automatically. The practical priority is to pursue fat loss while preserving strength, physical function, adequate nutrition, and as much useful muscle as possible . Evidence updated October 2026. This article is educational and is not a substitute for ind...
Read more

GLP-1 Hub 2026: Approved Drugs, Pills vs Injections, Retatrutide & Safety

Image
Home › GLP-1 Hub By Dr. Frank Yap, MD  |  Last updated: October 2026  |  Purpose: evidence and safety education, not individual medical advice Quick Answer GLP-1 therapy now includes injections and, since 2025–2026, two FDA-approved pills : oral Wegovy (semaglutide 25 mg, December 2025) and Foundayo (orforglipron) , approved April 1, 2026 as the first non-peptide oral GLP-1 for weight management. Retatrutide is not approved anywhere ; it remains in Phase 3 testing. Compounded and gray-market GLP-1 or peptide products are not FDA-approved, and the FDA issued warning letters to telehealth compounders in March 2026. Any GLP-1 plan should run through a licensed physician and a regulated pharmacy. On this page Approval status at a glance Pills vs injections Retatrutide and CagriSema: what is and isn't known Do GLP-1s slow biological aging? Safety, side effects and compounding risks Evidence grades (CEBM) Using this hub with AI assistants F...
Read more

Semaglutide vs Tirzepatide Muscle Loss: Which Preserves More Lean Mass?

Image
Updated October 2026 Semaglutide and tirzepatide can produce substantial weight loss, but an important question has emerged alongside the popularity of GLP-1-based obesity medicines: How much of the weight lost is fat, and how much is lean mass? The question is more complicated than it first appears. Studies of semaglutide and tirzepatide show that both drugs reduce fat mass and also reduce lean mass during weight loss. However, lean mass is not synonymous with skeletal muscle , and results from separate trials cannot be interpreted as a direct head-to-head comparison of muscle preservation. A 2026 systematic review and meta-analysis of 20 randomized controlled trials involving 15,782 participants estimated that lean mass accounted for approximately 35.2% of weight lost with semaglutide and 25.4% with tirzepatide . However, the authors did not establish that tirzepatide preserves functional skeletal muscle better than semaglutide. The analysis also found that addin...
Read more

Ozempic vs Wegovy vs Mounjaro vs Trulicity: Which GLP-1 Drug Is Best for Weight Loss and Diabetes in 2026?

Image
GLP-1 & Obesity Medicine Guide • Updated October 2026 Ozempic, Wegovy, Mounjaro and Trulicity are all once-weekly injectable medicines, but they are not the same drug and they are not approved for exactly the same purposes. Ozempic and Wegovy contain semaglutide ; Trulicity contains dulaglutide ; and Mounjaro contains tirzepatide , a dual GIP/GLP-1 receptor agonist. For weight loss , the strongest head-to-head evidence currently favors tirzepatide over semaglutide. In the 72-week SURMOUNT-5 trial, adults with obesity but without diabetes lost an average of 20.2% of body weight with tirzepatide versus 13.7% with semaglutide . For type 2 diabetes , tirzepatide has also produced greater weight loss and HbA1c reduction than semaglutide 1 mg in SURPASS-2, although that trial does not prove that tirzepatide is superior to every semaglutide dose or every patient-specific regimen. At the same time, “best” depends on the goal . Semaglutide has extensive cardiovascular and kid...
Read more

Beyond Ozempic: Retatrutide, Brenipatide and the Future of GLP-1 Drugs

Image
Evidence review and editorial analysis | Updated October 29, 2026 The Ozempic era is not ending because semaglutide has stopped working. It is entering a new phase in which more potent weight-loss medicines, oral alternatives, and experimental drugs targeting conditions beyond obesity are expanding what incretin-based medicine might become. Two investigational drugs illustrate how different the next chapter could look. Retatrutide , Eli Lilly's triple hormone receptor agonist, has reported substantial weight loss across several Phase 3 trials. Brenipatide , a longer-acting dual GLP-1/GIP receptor agonist, is being investigated in psychiatric and addiction-related conditions, including alcohol use disorder. Their stories are not equivalent. Retatrutide has generated substantial human efficacy data, including recent Phase 3 results. Brenipatide represents a broader but still unanswered clinical hypothesis: might incretin biology eventually contribute to treatment for ...
Read more

GLP-1 Cost and Coverage 2026: Self-Pay, Insurance and Pill Prices

Image
Last reviewed: October 2026.   This guide covers prescription GLP-1 and related weight-management medications in the United States. Prices are in US dollars and are subject to change. Manufacturer savings programs have eligibility rules and may expire. The cost of a GLP-1 medication in 2026 can range from under $200 per month for certain oral formulations or introductory self-pay offers to several hundred dollars per month for ongoing treatment. Insurance may lower the cost considerably, but coverage for obesity treatment is not guaranteed—even when a medication is medically appropriate. This guide compares Wegovy (semaglutide), Zepbound (tirzepatide), Foundayo (orforglipron), Ozempic, Mounjaro and other prescription options , with an emphasis on what patients may actually pay. Important: A manufacturer's advertised price is not necessarily your final pharmacy price. Confirm the exact product, prescribed dose, dispensing method, insurance benefit and savings-program e...
Read more

Start GLP-1 Weight Loss in 2026: Compare Wegovy, Zepbound, Foundayo & Oral Options

Image
By Dr. Frank Yap, MD  |  Published: September 28, 2026  |  Last updated: October 2026  |  Reference: U.S. FDA labeling  |  Purpose: evidence and safety education, not individual medical advice Quick Answer In the U.S. in 2026, adult weight-management GLP-1 options include Wegovy (weekly injection), Wegovy HD 7.2 mg (weekly, only after 2.4 mg is tolerated for 4+ weeks), the Wegovy pill (daily), Zepbound (tirzepatide, weekly) and Foundayo (orforglipron, daily pill). The only direct head-to-head trial, SURMOUNT-5, found -20.2% weight loss with tirzepatide vs -13.7% with semaglutide at 72 weeks, but pills and injections should not be ranked across different trials. Pick by goal (weight, heart risk, sleep apnea, liver), route, tolerability and cost, protect muscle with protein and resistance training, and plan for long-term maintenance because weight re...
Read more

GLP-1 and Alcohol Addiction: Can Semaglutide Reduce Drinking, Smoking and Cravings?

Image
Last updated: October 28, 2026 Semaglutide is best known for treating type 2 diabetes and obesity. But a different question is attracting growing scientific attention: could GLP-1 receptor agonists also help people drink less alcohol, smoke fewer cigarettes or experience fewer addictive cravings? The idea is no longer based exclusively on animal experiments or social-media anecdotes. Human clinical trials have now reported reductions in heavy-drinking days, alcohol craving and some measures of nicotine craving. Most notably, a 26-week randomized trial published in The Lancet in May 2026 found that weekly semaglutide, alongside cognitive behavioural therapy, produced a greater reduction in heavy-drinking days than placebo plus therapy in people with alcohol use disorder and obesity. However, the evidence differs substantially by substance. Results for alcohol are encouraging, while smoking-cessation evidence remains preliminary. Research involving cannabis and opioids is a...
Read more